EryDel is a multi-asset, clinical stage biopharmaceutical company headquartered in Bresso (Milan), Italy dedicated to developing and commercializing novel treatments for rare diseases with high unmet need. In 2018 EryDel received the “Most Innovative StartUp Italia Award” chosen from startups across all industries. EryDel specializes in the delivery of drugs using the patient’s own red blood cells. The lead product candidate, EryDex, is currently in Phase III development for the treatment of Ataxia Telangiectasia (AT), a rare neurological disorder for which no established therapy is currently available. EryDex received Orphan Drug designation for the treatment of AT both from FDA and EMA
